Elranatamab as Maintenance Therapy

Phase II Study of Elranatamab as Maintenance Therapy Post Ciltacabtagene-autoleucel(Cilta-cel) in Patients With Clinical High Risk Relapsed Myeloma

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
39 patients (estimated)
Sponsors
Moffitt Cancer Center
Collaborators
Pfizer
Tags
Bispecific Antibody, B-Cell Maturation Antigen (BCMA), High Risk, Maintenance, Post-CAR T
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
2110
NCT Identifier
NCT06947083

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.